abstract |
The present invention relates to a serotonin h5-HT1B receptor antagonist, (R) -N- [5-methyl-8- (4-methyl-1-piperazinyl) -1,2,3,4-tetrahydro-2-naphthyl]. A novel form of a salt of -4-morpholinobenzamide, (R) -N- [5-methyl-8- (4-methyl-1-piperazinyl) -1,2,3,4-tetrahydro-2-naphthyl] - Form 4-morpholinobenzamide monohydrobromide and methods for its preparation. The invention also relates to a pharmaceutical composition comprising a novel form of the compound. SHE |